Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl (OncoOne)
Former Shire execs set up shop to take a shot at 'under the radar' cancer target
In December 2016, Shire abandoned a cancer drug targeting oxMIF it had swallowed as part of its $32 billion buyout of Baxalta earlier that year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
